息性全身化疗期间身体组成的纵向变化以及转移性结直肠癌的生存结果
Hyehyun Jeong1, Yousun Ko2, Kyung Won Kim3
1Department of Oncology, Asan Medical Center, Seoul 05505, South Korea.
World journal of gastrointestinal oncology
|June 9, 2025
概括
转移性结直肠癌的缓解化疗经常会改变身体成分. 新出现的肉症和骨髓炎预测生存率较低,而肥胖与改善的结果相关,提供预后价值.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 身体组成分析 身体成分分析
背景情况:
- 转移性结直肠癌 (mCRC) 的化疗可以改变身体成分,影响肌肉和脂肪.
- 需要纵向数据来了解mCRC患者的这些身体组成变化.
研究的目的:
- 为了评估mCRC的息化疗期间身体组成的变化.
- 为了确定这些身体组成变化的预后意义.
主要方法:
- 对接受息化疗的1805名mCRC患者 (2008-2017年) 的回顾性分析.
- 用人工智能软件 (AID-UTM) 在多个时间点分析的计算机断层扫描 (CT) 扫描.
- 时间依赖的考克斯回归用于评估身体组成和生存之间的关联.
主要成果:
- 超过54%的患者在治疗期间经历了显著的身体组成变化.
- 新出现的肉症 (9.1%) 和骨髓炎 (19.2%) 与较低的存活率有关 (HR分别为2.55和2.37).
- 内脏和皮下肥胖与改善的生存率有关 (HR分别为0.69和0.78).
结论:
- 在mCRC缓和化疗期间,身体构成异常,特别是骨髓炎,是常见的.
- 身体组成的变化,包括肉症和肥胖症,提供了有价值的预后信息.
- 综合体构成评估可以在没有额外测试的情况下增强预后评估.
相关概念视频
Cancer Survival Analysis
329
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
329
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


